TW
ALNY icon

TrinityPoint Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

TrinityPoint Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-728
Closed -$200K – 336
2024
Q3 		$200K Buy
+728
New +$190K 0.03% 319

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

TrinityPoint Wealth's ALNY Position: Q4 2024 in Review

TrinityPoint Wealth sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 728 shares — an estimated $200K sold.

TrinityPoint Wealth first reported a position in ALNY in Q3 2024 and held it in 1 quarter. The position peaked at $200K in Q3 2024. 593 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

  • TrinityPoint Wealth reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • TrinityPoint Wealth sold 728 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $200K.
  • TrinityPoint Wealth first reported a position in Alnylam Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • TrinityPoint Wealth's Alnylam Pharmaceuticals position peaked at $200K in Q3 2024.
  • 593 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on TrinityPoint Wealth's 13F filing for Q4 2024, filed 14 Feb 2025.